Biosyent Inc (OTCPK:BIOYF)
$ 7.35 0.16 (2.23%) Market Cap: 88.74 Mil Enterprise Value: 68.12 Mil PE Ratio: 16.90 PB Ratio: 3.45 GF Score: 98/100

Q4 2020 Biosyent Inc Earnings Call Transcript

Mar 17, 2021 / NTS GMT
Release Date Price: $5.76 (-1.71%)
RenÃ;C. Goehrum
BioSyent Inc. - Chairman, CEO & President

© -

Hello. Welcome to the BioSyent Inc. Q4 and Fiscal Year 2020 Results Presentation. My name is René Goehrum, and I'm the President and CEO of the company.

I'm going to start the presentation with a look at our sales, EBITDA and net income after tax for the quarter ended December 31, 2020. So this quarter represented our 42nd consecutive profitable quarter. Our sales were up 3% in the quarter to the year ago, reaching $5.72 million, and that was made up with a few puts and takes. On the put side, the Canadian pharmaceutical business was up 7% in dollars versus the year ago, and the legacy business was up 180% versus the year ago. But remarkably as well, our international pharmaceutical business was down 87% in the quarter. The net-net of all those puts and takes was growth of 3% corporately.

On the income side, we had impacts of significant investment in growth assets. So we've been launching 3 products, namely Tibella, Combogesic and FeraMAX Pd. And as a group, we've invested just under $700,000 in those 3 assets

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot